FDA Approves Genentech ’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis

South San Francisco, CA -- December 14, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news